The EIC Accelerator beneficiary Axiles Bionics closes the first €6 Million of a €8 Million Series A financing to accelerate global expansion rollout and breakthrough bionic technology. The investment round has PE Group as the lead investor, and it is supported by the EIC Fund, Finance&Invest.brussels1, entrepreneurs, private investors and the management.
The funding will make it possible to drive the international expansion of Lunaris, the most advanced biomimetic prosthetic foot, now CE and FDA approved and recognised in multiple countries. Additionally, it will also permit to advance the next generation of smart bionic mobility solutions, expected to be launched in the coming years.
Axiles Bionics and Lunaris: discover their innovations
Axiles Bionics is a deeptech and medtech spin-off from Brubotics at the Vrije Universiteit Brussel (VUB). Their EIC Accelerator Solaris Project started in 2023 and aims to fill the clear world-wide market gap with next-generation bionic prostheses, creating a revolutionary cost-effective market concept Prosthetics-as-a-Service (PraaS), such as Lunaris.
These next-generation bionic prostheses mark a breakthrough in restoring lifelike movement for lower limb amputees. It is the foundation for new prosthetic technology, offering unmatched biomechanical agility and responsiveness. Clinical adoption is rising sharply, driven by a growing demand from patients and professionals seeking smarter solutions that move beyond traditional prosthetics.
Currently in advanced development, Axiles Bionics’ breakthrough bionic technology merges robotics, artificial intelligence, and human biomechanics to unlock a new dimension of movement. By elevating human-machine synergy to unprecedented levels, it promises to transform mobility and significantly enhance quality of life for people with limb loss. About the future of Axiles Bionics, its founder and CEO, Pierre Cherelle, said:
We envision a future where advanced bionics become standard, enhancing lives with superior mobility, health, and wellbeing. This funding is a vote of confidence in our vision, our team, and the patients we serve. Lunaris has proven that intuitive, lifelike mobility is achievable today. With our pipeline of bionic technologies, we aim to raise the bar once more — and reshape the global standard of prosthetic technology.
The newly announced Series A financing round
The funding will fuel the international commercialization of Lunaris, which blends adaptive mechanics with embedded intelligence to deliver intuitive and natural motion. CE-marked, FDA-cleared, and accredited across multiple countries, Lunaris is rapidly gaining adoption in clinical settings. The funding will also accelerate Axiles Bionics’ work on the next generation of bionic devices, currently in advanced development.
PE Group is the lead investor in the financing round, also supported by the EIC Fund, Finance&Invest.brussels1, entrepreneurs, private investors and the management. Svetoslava Georgieva, Chair of the European Innovation Council (EIC) Fund Board, said:
The EIC Fund is proud to participate in this funding round, supporting a European deeptech company that has already demonstrated impressive commercial success and clinical achievements. Axiles Bionics exemplifies the kind of science-driven innovation Europe needs to stay globally competitive in health technology and human-centric robotics.
About Axiles Bionics
Founded in 2019 as a spin-off from Brubotics at the Vrije Universiteit Brussel (VUB), Axiles Bionics is a EIC Accelerator Belgian deep/medtech company pioneering the future of human-machine interaction. Axiles Bionics holds a strong and growing IP portfolio, and its 15-person multidisciplinary team is composed of over two-thirds engineers, driving a culture of innovation and technical excellence. It has been recognized with major awards such as the European Innovation Award, the Innovative Start-up Award.
Find out more about the EIC Accelerator Solaris Project, visiting the Horizon Europe database and the company official website.
This article is based on the official press release issued on 24 June 2025, by Axiles Bionics.
DISCLAIMER: This information is provided in the interest of knowledge sharing and should not be interpreted as the official view of the European Commission, or any other organisation.